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The insulin disulfide reducing thioredoxin system from E.cob was used to investigate a possible mechanism 
of de~adat~on For the two somatom~ins, insulin-like growth factor I and II (IGF-I and -II). The amounts 
of IGF-I and -11 remaining after degradation were measured by use of human placenta radioreceptor assay. 
The results show that both IGF-I and -II were as sensitive to disulfide reduction as insulin. 
1. INTRODUCTION 
The somatomedins are a family of poIypeptide 
hormones with growth-stimulating and insulin-like 
activities in vitro [l-3]. Insulin-like growth factor 
I (IGF-I) and II (IGF-ZI), two members of the 
somatomedin family purified to homogeniety from 
human plasma, are low molecular mass peptides of 
7.5 kDa f4,5]. Both have a high degree of sequence 
homology to proinsulin. This sequence homoiogy 
which includes 3 disulfide bridges also present in 
insulin has been used to predict conformational 
models of IGF-I and -11 based on the known struc- 
ture of insulin [6]. 
The reduced form of thioredoxin [thioredoxin- 
(SH)2] is an efficient reductant of certain exposed 
protein disulfides 17-91. The disulfide bridges of 
insulin and proinsulin are efficiently reduced in 
vitro by thioredoxin-{SH)2 from rat liver and 
E~c~er~c~i~ co& [7-g]. The physiological impor- 
tance of this process is still unclear, but one 
hypothesis is that the first step in degradation of 
insulin in vivo, is an enzymatic reduction of 
disulfide bonds followed by proteolytic degrada- 
tion of free A and B chains [lO,ll]. It has been 
suggested that the degradation of insulin occurs 
after binding to its receptor, followed by inter- 
nalization of the receptor-hormone complex [ 121. 
To elucidate a possible mechanism of degrada- 
tion. and to study the reactivity of disulfide bonds 
in IGF-I and -11, we have used the thioredoxin 
system. The results show that both IGF-I and -II 
were degraded by thioredoxin-(SH)2 with the same 
or higher efficiency as insulin. 
2. MATERIALS AND METHODS 
2.1. ~a~er~ai~ 
Thioredoxin and thioredoxin reductase were 
prepared from E, coii B as previously described in 
[13,14]. IGF-I and -II were purified to homogenei- 
ty from human plasma according to the method of 
Enberg et al. 1151. 
Porcine insulin was obtained from Novo A/S 
(Denmark) and NADPH from Sigma (MO, USA). 
All other chemicals were of laboratory analytical 
grade. 
2.2, ~~~u~fi~~ and ~~ky~ati~~ 
A reaction buffer composed of 0.05 M Tris, pH 
7.4,0.2010 human serum albumin and I mM EDTA 
was used for all dilutions. Stock solutions of 0.8 
mM NADPH, 500 pM thioredoxin, 10 FM 
thioredoxin reductase and 5 mM iodoacetic acid 
were used. 
A reaction mixture was prepared fresh from 500 
pm reaction bufferm 2 ~1 or 500 FM thioredoxin 
and 10 ~1 of 10 FM thioredoxin reductase. 
The degradation studies were performed at 
room temperature. To 200 or 500 ng pure peptide 
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(lyophilized in siliconized glass tubes) 60~1 of reac- 
tion buffer was added. Ten ,J of 0.8 mM NADPH 
was added and a control sample of 10~1 was taken 
at time 0. The reaction was started by addition of 
10 ~1 reaction mixture and 10-J samples were 
taken at the specified times. The reactions were ter- 
minated by addition of 5 ~1 of 5 mM iodoacetic 
acid followed by 1 h incubation at room 
temperature. 
2.3, Radioreceptor assays 
Labelling of insulin, IGF-I and II with 12’1 was 
done with the lactoperoxidase method, followed 
by separation of the labelled peptides from 1251 by 
ion-exchange chromatography on CM-cellulose as 
in [ 161. A radioreceptor assay utilizing human 
placental membranes as matrix, was used to 
measure the amount of non-degraded material 
[17]. All values are expressed as percent of the 
amount of peptide originally present in the starting 
material. 
3. RESULTS 
The effect of disulfide reduction of insulin on its 
receptor binding was tested by incubation of 
0.4-0.8 FM insulin with thioredoxin and 
thioredoxin reductase in the presence of NADPH. 
To inactivate completely the thioredoxin system 
the reaction was stopped by alkylation of nascent 
sulfhydryl groups by addition of excess iodoacetic 
acid. As seen from table 1, the receptor binding ac- 
tivity of insulin was rapidly lost upon incubation, 
which is consistent with reduction and alkylation 
of essential disulfide bonds in the molecule. Con- 
Table 1 
Results of degradation by the thioredoxin system 
min IGF-I IGF-II Insulin 
0 96.6 11.6 94.3 2.3 102.0 5.0 
0.5 nd 73.5 28.1 nd 
1 39.7 2.7 38.3 5.5 51.3 8.1 
2 27.9 8.7 21.7 1.5 42.7 3.4 
5 10.7 0.8 7.8 2.3 9.3 0.5 
The values are expressed in percent of the peptide 
originally present in the starting material. Each value 
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Fig.1. Rate of degradation for insulin (H), pure 
human IGF-I (o--o) and IGF-II (H) at concentra- 
tions between 0.4 and 0.8 ,&I, by the thioredoxin 
system. Thioredoxin was prepared from E. coli. The 
amount of non-degraded material was measured by 
human placenta radioreceptor assay. The values are ex- 
pressed as percent of the peptide originally present in the 
starting material. Each point represents the mean of 3 
experiments. 
trol samples exposed only to excess iodoacetic acid 
showed full receptor binding activity, excluding 
any detrimental effect of iodoacetic acid. 
Incubations of either IGF-I or -11 with the 
thioredoxin system at similar concentrations to in- 
sulin, also gave a rapid degradation of both pep- 
tides (table 1). The rate of degradation was similar 
for both IGF-I and -11, and identical to or higher 
than that for insulin (fig. 1). These results are con- 
sistent with essential reactive disulfides in both 
IGF-I and -II, and as for insulin, no decreased 
binding of IGF-I and -11 exposed only to iodo- 
acetic acid was observed. 
4. DISCUSSION 
The degradation of insulin in vivo occurs mainly 
in the liver and kidney, while the remainder is 
degraded by peripheral tissue [18]. At the cellular 
level 3 enzyme systems have been investigated, in- 
sulin protease, glutathione insulin transhydrogen- 
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ase (GIT) and lysosomal enzymes. It has been 
shown that a prerequisite for the degradation of in- 
sulin is receptor binding, and an internalization of 
the receptor-hormone complex [ 181. 
Based on the conformational models of IGF-I 
and -11 by Blundell et al., we assumed that the in- 
sulin disulfide reducing thioredoxin system, might 
be used to study a possible mechanism of degrada- 
tion for the somatomedins in vitro. Our results 
show that receptor binding of IGF-I and -11 re- 
quires intact disulfide bridges. Furthermore the 
results demonstrate that the reactivity of disulfides 
in IGF-I, IGF-II and insulin are similar, using 
thioredoxin-(SH)2 as a probe. This is in accordance 
with the predicted conformational models [6]. The 
number of disulfides in IGF-I and -11 reacting with 
thioredoxin-(SH)2 were not determined here due to 
the limited amounts of pure material available. In- 
stead, insulin with its well characterized reactivity 
with thioredoxin [7] was used for comparison. 
When larger amounts of IGF-I and -II are 
available, a quantitation and identification of the 
reactive disulfides by titration of the nascent 
sulfhydryl groups with radioactively labeled 
iodoacetic acid will be possible. 
In previous investigations utilizing different en- 
zyme preparations from rat liver [19], rat kidney 
[20], rat skeletal muscle [21] and human leucocytes 
[22], the rate of degradation of somatomedins has 
been compared to insulin. The results show that 
both IGF-I and -11 could be degraded by the same 
enzyme systems as insulin. The rate of degrada- 
tion, however, was less than that for insulin. This 
is in contrast to our results, in which both IGF-I 
and -11 were degraded with the same or higher 
potency as insulin. 
In conclusion, this study shows that the disulfide 
reducing enzyme thioredoxin, normally present in 
mammalian cells 123,241, degrades both IGF-I and 
-11 under physiological conditions. Whether this 
system has any physiological importance in vivo, 
will require further studies. 
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